Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Antiretroviral initiation is associated with increased skeletal muscle area and fat content.

Erlandson KM, Fiorillo S, Masawi F, Scherzinger A, McComsey GA, Lake JE, Stein JH, Currier JS, Brown TT.

AIDS. 2017 Aug 24;31(13):1831-1838. doi: 10.1097/QAD.0000000000001558.

PMID:
28590329
2.

Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (HAART).

Kumar NS, Shashibhushan J, Malappa, Venugopal K, Vishwanatha H, Menon M.

J Clin Diagn Res. 2015 Jul;9(7):OC05-8. doi: 10.7860/JCDR/2015/12979.6183. Epub 2015 Jul 1.

3.

Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

da Cunha J, Maselli LM, Stern AC, Spada C, Bydlowski SP.

World J Virol. 2015 May 12;4(2):56-77. doi: 10.5501/wjv.v4.i2.56. Review.

4.

Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria.

Iwuala SO, Lesi OA, Fasanmade OA, Sabir AA, Olamoyegun MA, Okany CC.

AIDS Res Treat. 2015;2015:402638. doi: 10.1155/2015/402638. Epub 2015 Mar 2.

5.

HIV-associated lipodystrophy: a review from a Brazilian perspective.

Alves MD, Brites C, Sprinz E.

Ther Clin Risk Manag. 2014 Jul 17;10:559-66. doi: 10.2147/TCRM.S35075. eCollection 2014. Review.

6.

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.

Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Tebas P, Melbourne K, Ha B, Jahed NC, McComsey GA.

AIDS. 2013 Aug 24;27(13):2069-79. doi: 10.1097/QAD.0b013e328361d25d.

8.

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.

Bedimo R.

HIV AIDS (Auckl). 2011;3:69-79. doi: 10.2147/HIV.S14561. Epub 2011 Jul 10.

9.

Genes linked to energy metabolism and immunoregulatory mechanisms are associated with subcutaneous adipose tissue distribution in HIV-infected men.

Irvin MR, Shrestha S, Chen YD, Wiener HW, Haritunians T, Vaughan LK, Tiwari HK, Taylor KD, Scherzer R, Saag MS, Grunfeld C, Rotter JI, Arnett DK.

Pharmacogenet Genomics. 2011 Dec;21(12):798-807. doi: 10.1097/FPC.0b013e32834b68f9.

10.

Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study.

Lake JE, Wohl D, Scherzer R, Grunfeld C, Tien PC, Sidney S, Currier JS.

AIDS Care. 2011 Aug;23(8):929-38. doi: 10.1080/09540121.2010.543885. Epub 2011 Jun 24.

11.

Regional anthropometry changes in antiretroviral-naïve persons initiating a Zidovudine-containing regimen in Mbarara, Uganda.

Thompson V, Medard B, Taseera K, Chakera AJ, Andia I, Emenyonu N, Hunt PW, Martin J, Scherzer R, Weiser SD, Bangsberg DR, Tien PC.

AIDS Res Hum Retroviruses. 2011 Jul;27(7):785-91. doi: 10.1089/AID.2010.0272. Epub 2011 Feb 14.

12.

HIV protease inhibitors and obesity.

Anuurad E, Bremer A, Berglund L.

Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):478-85. doi: 10.1097/MED.0b013e32833dde87. Review.

13.

Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort.

Brown TT, Smurzynski M, Wu K, Bosch RJ, McComsey GA.

Antivir Ther. 2009;14(6):853-8. doi: 10.3851/IMP1300.

14.

The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy.

Shlay JC, Sharma S, Peng G, Gibert CL, Grunfeld C; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA); International Network for Strategic Initiatives in Global HIV Trials (INSIGHT).

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304. doi: 10.1097/QAI.0b013e3181aa1308.

15.

Adherence to the Mediterranean diet is associated with a lower risk of body-shape changes in Croatian patients treated with combination antiretroviral therapy.

Turcinov D, Stanley C, Rutherford GW, Novotny TE, Begovac J.

Eur J Epidemiol. 2009;24(5):267-74. doi: 10.1007/s10654-009-9330-2. Epub 2009 Mar 26.

16.

The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.

Flint OP, Noor MA, Hruz PW, Hylemon PB, Yarasheski K, Kotler DP, Parker RA, Bellamine A.

Toxicol Pathol. 2009 Jan;37(1):65-77. doi: 10.1177/0192623308327119. Epub 2009 Jan 26. Review.

17.

Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways.

Caron M, Vigouroux C, Bastard JP, Capeau J.

PPAR Res. 2009;2009:507141. doi: 10.1155/2009/507141. Epub 2008 Dec 30.

18.

Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial.

Sattler FR, Rajicic N, Mulligan K, Yarasheski KE, Koletar SL, Zolopa A, Alston Smith B, Zackin R, Bistrian B; ACTG 392 Study Team.

Am J Clin Nutr. 2008 Nov;88(5):1313-21.

19.

Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors.

Grunfeld C, Kotler DP, Arnett DK, Falutz JM, Haffner SM, Hruz P, Masur H, Meigs JB, Mulligan K, Reiss P, Samaras K; Working Group 1.

Circulation. 2008 Jul 8;118(2):e20-8. doi: 10.1161/CIRCULATIONAHA.107.189623. Epub 2008 Jun 19. No abstract available.

20.

Supplemental Content

Support Center